Castle Biosciences (CSTL) Enterprise Value (2018 - 2026)

Castle Biosciences has disclosed Enterprise Value across 9 years of filings, most recently posting -$261.7 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$261.7 million, up 4.89% year-over-year; the trailing twelve-month figure through Mar 2026 was -$261.7 million (up 4.89% YoY), and the FY2025 annual result was -$299.5 million, down 2.17% from the prior year.
• Enterprise Value came in at -$261.7 million for Q1 2026 at Castle Biosciences, up from -$299.5 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$225.5 million in Q2 2023 to a low of -$309.0 million in Q1 2022.
• The 5-year median for Enterprise Value is -$266.0 million (2022), against an average of -$265.2 million.
• Across the five-year window, Enterprise Value rose 26.76% in 2022 and dropped 21.8% in 2024, its largest moves.
• Castle Biosciences' Enterprise Value stood at -$258.6 million in 2022, then gained by 6.0% to -$243.1 million in 2023, then decreased by 20.58% to -$293.1 million in 2024, then retreated by 2.17% to -$299.5 million in 2025, then advanced by 12.62% to -$261.7 million in 2026.
• The last three Enterprise Value figures came in at -$261.7 million (Q1 2026), -$299.5 million (Q4 2025), and -$287.6 million (Q3 2025), per Business Quant data.